| 1 |
Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in advanced breast cancer [J]. N Engl J Med, 2016, 375(20): 1925-1936.
|
| 2 |
Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer [J]. J Clin Oncol, 2017, 35(32): 3638-3646.
|
| 3 |
Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line Ribociclib plus Letrozole versus placebo plus Letrozole in hormone receptor-positive, HER2-negative advanced breast cancer [J]. Ann Oncol, 2018, 29(7): 1541-1547.
|
| 4 |
Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial [J]. Lancet Oncol, 2018, 19(7): 904-915.
|
| 5 |
Im SA, Lu YS, Bardia A, et al. Overall survival with Ribociclib plus Endocrine therapy in breast cancer [J]. N Engl J Med, 2019, 381(4): 307-316.
|
| 6 |
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus Palbociclib versus Fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J]. Lancet Oncol, 2016, 17(4): 425-439.
|
| 7 |
Sledge GW, Jr., Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with Fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy [J]. J Clin Oncol, 2017, 35(25): 2875-2884.
|
| 8 |
Sledge GW, Toi M, Neven P, et al. The effect of Abemaciclib plus Fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial [J]. JAMA Oncol, 2019, 6(1): 116-124.
|
| 9 |
Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 [J]. J Clin Oncol, 2018, 36(24): 2465-2472.
|
| 10 |
Slamon DJ, Neven P, Chia S, et al. Overall survival with Ribociclib plus Fulvestrant in advanced breast cancer [J]. N Engl J Med, 2020, 382(6): 514-524.
|
| 11 |
Jiang Z, Li W, Hu X, et al. Tucidinostat plus Exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2019, 20(6): 806-815.
|
| 12 |
Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO-2 final progression-free survival analysis [J]. Adv Ther, 2013, 30(10): 870-884.
|
| 13 |
Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group [J]. J Clin Oncol, 2000, 18(22): 3758-3767.
|
| 14 |
Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial [J]. Lancet, 2016, 388(10063): 2997-3005.
|
| 15 |
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing Fulvestrant 250 mg with Fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [J]. J Clin Oncol, 2010, 28(30): 4594-4600.
|
| 16 |
Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial [J]. J Natl Cancer Inst, 2014, 106(1): djt337.
|
| 17 |
Zhang Q, Shao Z, Shen K, et al. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China [J]. Oncotarget, 2016, 7(35): 57301-57309.
|